A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Antiviral Activity of GS-9688 in Viremic Adult Subjects With Chronic Hepatitis B Who Are Not Currently on Treatment
Phase of Trial: Phase II
Latest Information Update: 28 Jan 2019
At a glance
- Drugs GS 9688 (Primary) ; Tenofovir alafenamide
- Indications Hepatitis B
- Focus Pharmacodynamics
- Sponsors Gilead Sciences
- 24 Oct 2018 Planned End Date changed from 1 Apr 2020 to 1 Feb 2020.
- 24 Oct 2018 Planned primary completion date changed from 1 Oct 2019 to 1 Sep 2019.
- 31 Aug 2018 Status changed from not yet recruiting to recruiting.